BACKGROUND
Despite ongoing prevention and educational efforts, an estimated 4.000 new HIV infections occur annually in Italy (7) . The typical evolution of viral and host markers of HIV infection are presented in Figure I . Investigations into virological and serological events that occur during the very early phase of HIV infection indicate that a high titre viraemia occurs generally during the second to third week after exposure ( Figure I ). This allows generalised seeding of the virus in susceptible tissue throughout the body. HIV genomic RNA is present before the patient has developed any detectable anti-HIV antibodies (1, 2) . Available evidence suggests that many new infections are caused by individuals unaware of their HIV infection (6) . Rapid HIV test recently approved by FDA can help reduce unrecognized infections by improving access to test in a clinical setting. Rapid testing can play an important role in HIV prevention and expand access to testing in clinical settings. It can help overcome some of the barriers to early diagnosis and improve linkage to care of infected persons (3). In order to give quick results in case of worker exposure during night shift or weekend work, a first rapid result is given by a commercial HIV assay. The key-word is No waiting, this reduces anxiety and offers an accurate assessment in cases of occupational exposure (such as accidental needle prick) (4, 5) . 
METHODS

Forty
HIV-1/2 Ag/Ab Combo Inverness Medical ®
This is a qualitative immunochromatographic test for the simultaneous detection of HIV p24 antigen (Ag) and antibodies (Ab) to HIV-1 and HIV-2 in human serum, plasma, or wool blood. The sample is added to the sample pad (50 μl and wait 30 minutes). The specimen is mixed with a biotinylated anti-p24 antibody and selenium colloid-antigen conjugate. This mixture continues to migrate through the solid phase to the immobilized avidin, recombinant antigens and synthetic peptides at the patient's window sites. To ensure assay validity, a procedural control is incorporated into the device and is labelled control. If it is not red the test is invalid. 
RESULTS
Forty-eight selected samples have registered these characteristics: 38 proved negative; 2 positive at the first step, but this result was not confirmed in WB, and 8 positive. We analyzed all them with the new POCT HIV1-2 Ag/Ab (Table 1) . Analytical performance (sensitivity and specificity) and diagnostic accuracy of 100% were recordered. It is noteworthy that the two serum resulting Ag-p24 positive by POCT were also confirmed by ELISA assay (ICD-HIVp24Ag7 Innogenetics ® , USA) ( Table 1) . The evaluation of possible interferences due to EBV, CMV, Toxo, HSV, Rubeo Antibodies or elevated level of total bilirubin does not give false results. 
